The Evolving Advanced RCC Treatment Landscape
June 26th 2023Researcher and clinician, Dr. Thomas Hutson reflects on the modern patient journey and shares his experience treating people with advanced RCC. Through the years, the advanced RCC treatment landscape has evolved significantly. In this two-part series brought to you by Eisai Inc., hear from oncologist Thomas Hutson, DO as he reflects on best practices for evaluating today’s treatment options.
Read More
Dr. Hutson on Lenvatinib/Everolimus Combo in RCC
November 5th 2016Thomas E. Hutson, DO, PharmD, director of the Genitourinary Oncology Program, Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the efficacy associated with the combination of levantinib (Lenvima) and everolimus (Afinitor) in patients with metastatic renal cell carcinoma (RCC).
Read More
Dr. Hutson Discusses the Phase III ATLAS Study in RCC
July 18th 2014Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).
Read More